NONPROVISIONAL APPLICATION FOR LETTERS PATENT
UNITED STATES OF AMERICA

Be it known that I, **YEA-YANG SU, PhD**, residing at **945 Alexis Way, Marietta, Georgia 30066**, a citizen of the United States, and I, **CHUN-CHE SHIH, MD, PhD**, residing at **No. 14, Lane 44, Tian Mu North Road, Taipei, Taiwan 112**, and I, **CHUN-MING SHIH, MD**, residing at **2F, No. 11-4, Alley 4, Lane 63, Yi-Li Street, Taipei, Taiwan 112**, and I, **SHING-JONG LIN, MD, PhD**, residing at **No. 320, 7F-1, Sec. 2, Shih-Pai Road, Taipei, Taiwan 112**, citizens of Taiwan, have invented certain new and useful improvements in an

AMORPHOUS OXIDE SURFACE FILM FOR METALLIC IMPLANTABLE DEVICES AND METHOD FOR PRODUCTION THEREOF

of which the following is a specification.

INVENTOR'S REPRESENTATIVES:

BARRY E. KAPLAN, ESQ.
ASHISH D. PATEL, ESQ.

MYERS & KAPLAN
INTELLECTUAL PROPERTY LAW, L.L.C.
1899 Powers Ferry Road
Suite 310
Atlanta, GA 30339
Telephone: (770) 541-7444
Facsimile: (770) 541-7448
Email: bkaplan@mkiplaw.com
Email: apatel@mkiplaw.com

1

AMORPHOUS OXIDE SURFACE FILM FOR METALLIC IMPLANTABLE DEVICES AND METHOD FOR PRODUCTION THEREOF

TECHNICAL FIELD

5

The present invention relates generally to surface treatments and/or coatings for metallic implantable devices, and more specifically to an amorphous oxide surface film for metallic implantable devices and method for production thereof.

10 The present invention is particularly advantageous for its ability to improve corrosion resistance and biocompatibility of metallic implantable stents, and thus, significantly reduce the degree of thrombosis and ensuing restenosis following deployment of same within the coronary artery.

15

BACKGROUND OF THE INVENTION

Commonly referred to as "stents", percutaneously introduced prosthetic devices are utilized to reinforce and maintain the

20 luminal integrity of diseased blood vessels. Of particular recognition and increased usage are intracoronary stents, which have, to date, exhibited increased clinical success due in part to industry manufacturers designing and providing stents

2

specifically manufactured to address the concerns of thrombosis and restenosis.

Specifically, available bare metallic stents characteristically and inherently possess a post-manufacturing oxide layer that tends to interact with the patient's blood and cellular wall following insertion and deployment of the stent within the patient's arteries. Accordingly, poor blood compatibility and/or cellular interaction of the stent with the intimal layer of the artery are dispositive of an adverse interaction, and are typically characterized by increased thrombogenicity and ensuing restenosis. That is, although application of stents have illustrated a reduction in both the incidence of restenosis and the potential of repeat revascularization compared to balloon angioplasty alone, 20% to 40% of patients receiving a stent still experience restenosis as a consequence of adverse stent interaction with the intimal layer of the patients' arteries.

Such adverse stent interaction may be exacerbated as a result of stent corrosion. That is, degradation products, such as metal ions, resulting from corrosion of the metallic stent (i.e., when exposed to physiological conditions) present

3

potential adverse biological effects, namely allergy, cytotoxicity, and carcinogenicity. Additionally, degradation products are well recognized for their proinflammatory effects, as the release of nickel, chromium and molybdenum ions from corroding metallic stents may trigger an immunological defense in the form of chronic inflammatory reactions that would, in turn, result in fibroblast activity and ensuing scar formation. Unfortunately, such inflammatory conditions not only expedite stent corrosion, and thus the release of nickel, chromium and molybdenum ions, but are a direct correlative result of increased thrombogenicity following stent deployment.

Accordingly, several surface treatments and/or coatings have been developed in an attempt to reduce the degree of thrombosis and ensuing restenosis following deployment of the stent into a patient's coronary artery. Such currently available coatings include gold, diamond-like carbon, heparin, silicon, amorphous SiC-H coatings, and drug-eluting coatings such as SIROLIMUS or TAXOL. Unfortunately, each such surface treatment and/or coating, and the methodologies utilized to apply and implement same, possess inherent disadvantages that render application of same overly complex, unduly expensive, and

4

ineffective, especially in view of the generally complex geometry of most available stents.

Specifically, although gold is generally recognized as a
5 highly biocompatible material, stents coated with a gold layer have typically showed no significant influence on the thrombotic event of the stent within the patient's artery, but have illustrated a significant increase in the risk of restenosis through the first year following deployment of the stent.
10 Expensive diamond-like carbon coating of stents is utilized to reduce the release of metallic ions from same, and although clinical application of such stents have illustrated a reduction in neointimal hyperplasia, the degree of reduction is not statistically significant.

15

With regard to heparin-coated stents, although clinical application of same is characterized by a reduction of platelet deposition, an elimination of cyclic blood flow variation, improved blood flow, and potential reduction of thrombogenicity,
20 such heparin-coated stents have not been shown to improve late vessel patency and neointimal hyperplasia.

Although silicon-based implantable devices are commonly utilized in a variety of medical applications, clinical research has shown that application of impermeable silicon-covered stents could result in increasing thrombogenicity and foreign-body reaction.

With respect to amorphous SiC-H (heavily n-doped hydrogen-rich) coatings, although no clinical trials of such stents have been reported, the coating process is recognizably complex. Typical processes require that the amorphous SiC-H be deposited over the stent surface via complicated plasma-enhanced chemical vapor deposition in an effort to increase the resistance of the surface film and reduce density of electronic states at grain boundaries; thus, reducing electrostatic charging between the stent surface and intimal layer of the artery.

At present, SIROLIMUS is one of the popular drug-eluting coatings utilized on stents, as it is a cell-cycle inhibitor, a natural macrocyclic lactone, and a potent immunosuppressive agent. Accordingly, SIROLIMUS was considered as a coating for stents as it was found during clinical research to inhibit the rate of proliferation of human smooth muscle cells and reduce intimal thickening in a model of vascular injury. Although

initial clinical application of SIROLIMUS-coated cardiovascular stents presented no significant clinical events such as stent thrombosis or repeat revascularization, many researchers question whether SIROLIMUS-coated stents are an actual cure to

5   thrombosis and ensuing restenosis, or merely a delay to the occurrence of same.

In addition to, or in lieu of, stent coatings and/or surface treatments, clinical researchers have proposed treatment

10   of the arterial wall via application of radiation utilizing ^{192}Iridium seeds in an attempt to reduce neointima formation following balloon angioplasty, and just prior to stent deployment. Unfortunately, however, irradiation of non-target tissue surrounding the arterial wall, in addition to exposure of

15   the operating person to the radiation, renders such treatment highly risky, especially in view of the fact that a relatively high threshold of radiation (approximately 4μCi) must be delivered and maintained to inhibit neointima formation. However, even with such radiation treatment, and following

20   implantation of the stent, it is shown that neointima thickening still occurs with implant time.

Accordingly, in an attempt to resolve the above-discussed disadvantages, much research has been conducted with regard to the post-manufacturing oxide layer that exists over bare metallic stents, and the interaction of same with the patient's intima. Specifically, because a surface oxide film is a semiconductor for electron transfer during the thrombosis process, it is recognized that the creation of more negatively-charged surface oxide could reduce thrombogenicity. Such a negatively-charged oxide surface may be achieved via metal passivation techniques conducted under controlled conditions, wherein such passivated metals tend to exhibit a much more stable oxide layer over their surface; thus, significantly contributing to corrosion resistance and relative inertness of the metallic stent when deployed in physiological conditions.

Of the various oxide layers commonly encountered over metallic stents, stents comprising polycrystalline oxide layers are recognized as being generally unsuitable for cardiovascular application, due in large part to the relatively high density of state in the band gap in the grain boundaries (i.e., oxide particle boundaries), wherein such a high density of state fails to satisfy the necessity of a low transfer current density for reduced thrombogenicity. That is, a lower density of state is

held to be a critical factor in determining the degree of thrombosis and restenosis following implantation of the stent.

Although, electropolishing and nitric acid passivation are techniques currently utilized to create desired protective oxide films over the stent surface for increased corrosion resistance and improved biocompatibility of same, such techniques still do not provide the requisite density of state of oxide particles or grains over the surface of treated metallic stent.

Therefore, it is readily apparent that there is a need for an amorphous oxide surface film for metallic implantable devices and method for production thereof, wherein the present invention may be utilized to manufacture a stent comprising corrosion resistance and enhanced biocompatibility, thereby significantly reducing the degree of thrombosis and ensuing restenosis following deployment of same within a physiological environment.

BRIEF SUMMARY OF THE INVENTION

Briefly described, in a preferred embodiment, the present invention overcomes the above-mentioned disadvantages and meets the recognized need for such an apparatus and method by

providing an amorphous oxide surface film for metallic implantable devices and method for production thereof, wherein the amorphous oxide film comprises a high concentration of oxygen, chromium and hydroxyl ions within the film, so as to

5 form a non-stoichiometric chromium oxide with significant negative charge; thereby, improving the corrosion resistance and biocompatibility of the metallic implantable device, and thus significantly reducing the degree of thrombogenicity and restenosis.

10

According to its major aspects and broadly stated, the present invention in its preferred form is an amorphous oxide surface film for metallic implantable devices and method for production thereof, comprising, in general, passivation

15 processes and solutions utilizing sodium nitrate (NaNO$_3$) as a preferred oxygen provider to facilitate formation of an amorphous oxide surface film over a selected implantable device.

More specifically, the present invention is an amorphous

20 oxide surface film for metallic implantable devices and method for production thereof, wherein an implant sample is preferably heated to an appropriate temperature within a saturated oxygen atmosphere such that the nanometer or sub-nanometer scale of

amorphous oxide particles form at a faster rate of nucleation than growth; thus, resulting in an amorphous oxide film comprising a high concentration of oxygen, chromium and hydroxyl ions therewithin, and, as such, a non-stoichiometric chromium oxide with significant negative charge.

Preferably, the formation of the present amorphous oxide film may be selectively obtained from one of either three passivation solutions (i.e., referred to herein as passivation solutions A, B and C) depending on the final application or end-use of the implants, as some implants, and the application thereof, favor an oxide film formed in an acidic solution, while others favor an amorphous oxide film formed in either an alkaline solution or a neutral solution.

Accordingly, passivation solutions A, B, and C preferably utilize sodium nitrate ($NaNO_3$) as the oxygen provider to facilitate formation of the present amorphous oxide layer. However, it should be recognized that other suitable nitrate compounds may be utilized in substitution of $NaNO_3$ to form the amorphous oxide film of the present invention over the selected implant, wherein such alternate nitrate compounds may include, without limitation and for exemplary purposes only, potassium

11

nitrate, ammonium nitrate, calcium nitrate, chromium nitrate, copper nitrate, iron nitrate, lead nitrate, and barium nitrate.

With specific regard to passivation solution A, preferred pH buffer chemicals include a combination of sodium bicarbonate ($NaHCO_3$), sodium carbonate (Na_2CO_3), and sodium hydroxide (NaOH), as such buffers function not only as good pH buffers at elevated temperatures, but further behave as oxygen donors at the processing temperature. It is contemplated, however, that the preferred pH buffer chemicals may be replaced with other chemicals, such as, for exemplary purposes only, phosphate or borate compounds, if no intervention of formation of the present amorphous oxide film occurs. Preferably, the ratio between $NaHCO_3$, Na_2CO_3, and NaOH is 1:1:1 for most applications, but may be adjusted to any ratio or as high as 1:1:10, or even 1:1:20, if a higher concentration of hydroxyl ion is required for the amorphous oxide film - such as in those circumstances wherein the amorphous oxide layer will be utilized as a platform for drug-loading.

Although passivation solution A provides a higher concentration of hydroxyl ions within the resulting amorphous oxide layer than passivation solution B, which provides little

to no hydroxyl ions within the amorphous oxide film as a result of the lower pH value of passivation solution B, amorphous oxide layers resulting from utilization of passivation solution B still preferably impart the implants with improved physical,

5   chemical, and biocompatibly favorable properties in view of traditional implant coatings and/or surface treatments.

With regard to passivation solution C, depending on the chemical composition of the alloys of the metallic implantable

10   device, the pH value of passivation solution C (preferably comprising $NaNO_3$) may be selectively adjusted to the range of approximately 6.5 to approximately 7.5 to effectively enhance the corrosion resistance of such metal-alloy devices. Accordingly, and preferably with the assistance of a pH meter,

15   neutral passivation solution C is preferably imparted with such a pH value by adjusting and titrating same via the addition of preferably small amounts of $NaHCO_3$ and diluted HCl solution.

Preferably, the processing temperature for each passivation

20   solution A, B or C must reach at least the boiling temperature of the respective solution in order to provide the highest density of oxygen ion concentration inside the resulting amorphous oxide surface film. It should be noted that the

13

processing time may be reduced with higher processing temperatures.

Preferably, to maintain the proper concentration of the various chemical components within passivation solutions A, B or C during the amorphous oxide formation processing, a condenser with running water circulating therearound is preferably utilized. Additionally, the glass container/flask utilized in implementing the present process may be replaced with other suitable containers of proper materials adapted to effectively handle the heat transfer of the present invention, and provide effective corrosion resistance to the high pH, low pH, or neutral pH of passivation solutions A, B or C, respectively.

The present invention contemplates that the amorphous oxide film processing preferably be performed as a final step in the manufacturing process of the implant; although, application of the present method may be utilized at any selected step of the manufacturing process to yield desired results.

Accordingly, a feature and advantage of the present invention is its ability to provide an implantable device comprising an amorphous oxide surface film that provides the

implantable device with excellent corrosion resistance to chloride-bearing solutions, such as body fluid, or tissue comprising high concentrations of chloride.

5   Another feature and advantage of the present invention is its ability to provide an implantable device comprising an amorphous oxide surface film that comprises a negative and stable open-circuit potential when exposed to body fluid or tissue; thus, ensuring a thrombosis-free condition.

10

Still another feature and advantage of the present invention is its ability to provide an implantable device comprising an amorphous oxide surface film having a negative charge thereover; thus, inhibiting the release of positively-

15   charged ions from the implantable device.

Still yet another feature and advantage of the present invention is its ability to provide a stent comprising an amorphous oxide surface film, wherein the high value of time

20   constant over the amorphous oxide surface film functions to retard the interaction between the stent and blood and/or intimal layer of an artery; thus, reducing thrombogenicity and ensuing restenosis.

A further feature and advantage of the present invention is its ability to provide a stent comprising an amorphous oxide surface film that functions to effectively minimize restenosis following deployment of same with a selected artery.

5

Still a further feature and advantage of the present invention is its ability to provide an implantable device comprising an amorphous oxide surface film that effectively provides and functions as a platform for drug-loading, wherein

10 such drug-loading may advantageously be effectuated without the assistance of a polymer as a result of the chemical and structural configuration of the present amorphous oxide layer.

These and other features and advantages of the present

15 invention will become more apparent to one skilled in the art from the following description and claims when read in light of the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

20

The present invention will be better understood by reading the Detailed Description of the Preferred and Alternate Embodiments with reference to the accompanying drawing figures,

16

in which like reference numerals denote similar structure and refer to like elements throughout, and in which:

FIG. 1 is a flow diagram of a method of amorphous oxide

5   surface film formation according to a preferred embodiment of the present invention;

FIG. 2 is an illustration of apparatus utilized to implement a method of amorphous oxide surface film formation

10   according to a preferred embodiment of the present invention;

FIG. 3 is an image of transmission electron microscopy of various oxide layers, including an amorphous oxide surface film according to a preferred embodiment of the present invention,

15   observed at low magnification;

FIG. 4 is an image of transmission electron microscopy of an amorphous oxide surface film according to a preferred embodiment of the present invention, observed at high

20   magnification;

FIG. 5A is a graphical diagrammatic representation of oxygen and chromium concentrations of an amorphous oxide surface

film according to a preferred embodiment of the present invention;

FIG. 5B is a graphical diagrammatic representation of
5   oxygen and chromium concentrations of an oxide film yielded through electropolishing processes;

FIG. 5C is a graphical diagrammatic representation of oxygen and chromium concentrations of a polycrystalline oxide
10   film;

FIG. 6 is a graphical diagrammatic representation of open circuit potential measurements of various oxide layers, including an amorphous oxide surface film according to a
15   preferred embodiment of the present invention;

FIG. 7 is a graphical diagrammatic representation of cyclic anodic polarization scanning curves of various oxide layers, including an amorphous oxide surface film according to a
20   preferred embodiment of the present invention;

FIG. 8A is a graphical diagrammatic representation of current density at open-circuit potential for an amorphous oxide

18

surface film according to a preferred embodiment of the present invention;

FIG. 8B is a graphical diagrammatic representation of current density at open-circuit potential for an oxide film yielded through electropolishing processes;

FIG. 8C is a graphical diagrammatic representation of current density at open-circuit potential for a polycrystalline oxide film;

FIG. 9 is a graphical diagrammatic representation of time constant versus degree of thrombosis for various oxide layers, including an amorphous oxide surface film according to a preferred embodiment of the present invention;

FIG. 10A is an image of a heparin-medicated implant comprising an amorphous oxide surface film according to a preferred embodiment of the present invention, illustrating degree of thrombosis;

FIG. 10B is an image of a heparin-medicated implant comprising an oxide film yielded through electropolishing processes, illustrating degree of thrombosis;

5   **FIG. 11A** is an image of an implant comprising an amorphous oxide surface film according to a preferred embodiment of the present invention, illustrating degree of neointimal hyperplasia;

10   **FIG. 11B** is an image of an implant comprising an oxide film yielded through electropolishing processes, illustrating degree of neointimal hyperplasia;

FIG. 11C is an image of an implant comprising a 15 polycrystalline oxide film, illustrating degree of neointimal hyperplasia; and,

FIG. 12 is a graphical diagrammatic representation of cyclic voltammetry for an amorphous oxide surface film according 20 to a preferred embodiment of the present invention, utilized as a platform for drug loading.

DETAILED DESCRIPTION OF THE PREFERRED

AND SELECTED ALTERNATIVE EMBODIMENTS

In describing the preferred and selected alternate embodiments of the present invention, as illustrated in **FIGS. 1-12**, specific terminology is employed for the sake of clarity. The invention, however, is not intended to be limited to the specific terminology so selected, and it is to be understood that each specific element includes all technical equivalents that operate in a similar manner to accomplish similar functions.

Referring specifically now to **FIGS. 1-2**, the present invention in a preferred embodiment is an amorphous oxide surface film 5 for metallic implantable devices, and method 10 for production thereof, wherein method 10 comprises the steps of degreasing 20, pre-heat treatment 25, rinsing 30, pickling 40, rinsing 50, passivation 60, rinsing 70, drying 80, and packing 90. As more fully described below, passivation step 60 of method 10 is preferably implemented via apparatus 100, wherein apparatus 100 preferably comprises flask 102, heater 104, thermometer 106 and condenser 108. Although passivation step 60 of method 10 is preferably implemented via apparatus 100, it

should be recognized that other suitable apparatuses, assemblies and/or equipment may be utilized to effectuate passivation step 60 to effectively yield amorphous oxide surface film 5 of the present invention.

5

Preferably, the present invention contemplates that amorphous oxide surface film 5 may be formed over any selected implantable device, and more specifically, over any implantable device manufactured from a suitable material, such as, for

10 exemplary purposes only, stainless steels (including, without limitation stainless steel 316, 316L, 316LVM, 316LN, 304, and/or 304L), MP35N alloy, Chromium-Cobalt alloys, NITINOL, Titanium, Ti-6Al-4V (i.e., titanium alloy), or Zirconium. Additionally, the present invention further contemplates that suitable

15 implantable devices preferably include, without limitation, wire, stents, grafting, and/or other implants of any selected geometric shape.

Preferably, method 10 begins with degreasing step 20,

20 wherein all as-manufactured implants, including stents, strips, disks, or the like, are preferably degreased with a suitable solvent, such as, for exemplary purposes only, isopropyl alcohol

or trichloroethylene, in order to remove post-manufacturing lubricants or other oily materials from the surfaces thereof.

Following thorough degreasing of the implants via degreasing step 20, all implants preferably undergo pre-heat treatment step 25 to ensure a high quality amorphous oxide surface film 5. Specifically, during pre-heat treatment step 25, all implants are preferably heat-treated at approximately 800°C, wherein stents are heated for at least two minutes, strips for at least five minutes, and disks for at least ten minutes; however, it should be recognized that the actual time for heat treatment is a function of the thickness of the implants/samples.

Preferably, the purpose of pre-heat treatment step 25 is to homogenize all heterogeneous structures within the implants, as such heterogeneous structures could create galvanic current inside the final amorphous oxide surface film 5, and therefore, adversely affect the otherwise various advantageous physical and chemical properties. If, however, the selected implants comprise an appropriate crystalline structure, pre-heat treatment step 25 may be selectively omitted.

Following pre-heat treatment step 25, and subsequent cooling of the implants, all implants are preferably cleansed or rinsed 30 via running water.

5   Thereafter, the implants preferably undergo pickling step 40, wherein pickling step 40 is preferably utilized to remove the oxide film that inherently resides over post-manufactured implants, and/or the materials utilized to manufacture the implant. Accordingly, such pre-existing oxide films are
10   preferably removed via a pickling solution comprising a first solution of approximately 10cc of hydrofluoric acid (concentrated) mixed with approximately 40cc of distilled water, and a second solution of approximately 25cc nitric acid (concentrated) mixed with approximately 25cc distilled water,
15   wherein the first and second solutions are preferably mixed together at a ratio of approximately 1:1 to make the requisite pickling solution for utilization in pickling step 40. The preferred pickling solution is preferably a recognized industrial and ASTM standard pickling solution typically
20   utilized to remove surface oxide films on stainless steel implants; however, it should be recognized that other suitable pickling solutions may be utilized for stainless steel implants and/or implants of any other selected metal or metal alloy.

Utilizing the above-described pickling solution, all implants are preferably ultrasonically pickled for approximately five to seventy minutes depending on the oxide film thickness over the implants.

5

Following pickling step 40, all implants are preferably cleansed or rinsed 50 via running water.

Thereafter, the implants are preferably introduced into preferred passivation solutions A, B or C via passivation step 60; thereby, resulting in the formation of amorphous oxide surface film 5 thereover. Preferably, passivation step 60 is conducted via utilization of apparatus 100, as more fully described below.

15

Generally, passivation solutions A, B and C preferably utilize sodium nitrate ($NaNO_3$) as the oxygen provider to facilitate formation of the present amorphous oxide surface film 5. However, it should be recognized that other suitable nitrate compounds may be utilized in substitution of $NaNO_3$ to form amorphous oxide surface film 5 of the present invention over the selected implant, wherein such alternate nitrate compounds may include, without limitation and for exemplary purposes only,

potassium nitrate, ammonium nitrate, calcium nitrate, chromium nitrate, copper nitrate, iron nitrate, lead nitrate, and barium nitrate.

5   With specific regard to passivation solution A, preferred pH buffer chemicals include a combination of sodium bicarbonate ($NaHCO_3$), sodium carbonate (Na_2CO_3), and sodium hydroxide (NaOH), as such buffers function not only as good pH buffers at elevated temperatures, but further behave as oxygen donors at the

10   processing temperature. It is contemplated, however, that the preferred pH buffer chemicals may be replaced with other chemicals, such as, for exemplary purposes only, phosphate or borate compounds, if no intervention of formation of the present amorphous oxide surface film 5 occurs. Preferably, the ratio

15   between $NaHCO_3$, Na_2CO_3, and NaOH is approximately 1:1:1 for most applications, but may be adjusted to any ratio or as high as approximately 1:1:10, or even approximately 1:1:20, if a higher concentration of hydroxyl ion is required for amorphous oxide surface film 5 - such as in those circumstances wherein

20   amorphous oxide surface film 5 will be utilized as a platform for drug-loading.

Accordingly, passivation solution A is preferably manufactured and utilized to impart amorphous oxide surface film 5 over the implants as follows: (1) approximately 100cc of distilled water is preferably mixed with approximately 1.5g of

5    $NaHCO_3$, approximately 1.5g Na_2CO_3, and approximately 1.5g of NaOH; (2) the resulting mixture is preferably agitated until all the ingredients are dissolved to yield a solution comprising a pH of approximately around or higher than 10; (3) approximately 50cc of the solution is preferably added to flask 102 of

10   apparatus 100; (4) approximately 50g of $NaNO_3$ is preferably added to the solution within flask 102; (5) the mixture within flask 102 is preferably heated, via heater 104 of apparatus 100, until the whole solution is boiling, whereupon the implants are then added to the boiling solution (i.e., boiling temperature is

15   approximately around 125°C, and may be measured via thermometer 106 of apparatus 100), and wherein bringing the solution to boiling temperature preferably provides the highest density of oxygen ion concentration inside the resulting amorphous oxide surface film 5; and, (6) to maintain the proper concentration of

20   the various chemical components within passivation solution A, condenser 108 of apparatus 100 is preferably utilized in conjunction with flask 102, wherein running water is preferably circulated through condenser 108.

Preferably, the optimal composition of passivation solution A approximately includes 1000g/l of $NaNO_3$, 15g/l of $NaHCO_3$, 15g/l of Na_2CO_3, and 15g/l of NaOH. However, depending upon the application of the implant and the desired properties of

5 amorphous oxide surface film 5 thereover, the composition of passivation solution A may approximately include ranges of 10-2000 g/l of $NaNO_3$, 0.1-50 g/l of $NaHCO_3$, 0.1-50 g/l of Na_2CO_3, and 0.1-50 g/l of NaOH.

10 Although passivation solution A provides a higher concentration of hydroxyl ions within the resulting amorphous oxide surface film 5 than passivation solution B, which provides little to no hydroxyl ions within amorphous oxide surface film 5 as a result of the lower pH value of passivation solution B,

15 amorphous oxide layers resulting from utilization of passivation solution B still preferably impart passivated implants with improved physical, chemical, and biocompatibly favorable properties in view of traditional implant coatings and/or surface treatments.

20

Accordingly, passivation solution B is preferably manufactured and utilized to impart amorphous oxide surface film 5 over the implants as follows: (1) approximately 50cc of water

28

(distilled or de-ionized water is preferred) is preferably added to flask 102 of apparatus 100; (2) to the water, approximately 50g of $NaNO_3$ is preferably added; (3) preferably, the pH of the resulting solution is diluted to a value of approximately 2 or

5   lower with a HNO_3 solution comprising an approximately 1:1 ratio of concentrated HNO_3 to water; (4) the entire solution within flask 102 is preferably heated, via heater 104, until boiling, whereupon the implants are then added to the boiling solution (i.e., boiling temperature is approximately around 125°C, and may

10   be measured via thermometer 106 of apparatus 100), and wherein bringing the solution to boiling temperature preferably also provides the highest density of oxygen ion concentration inside the resulting amorphous oxide surface film 5; and, (5) to maintain the proper concentration of the various chemical

15   components within passivation solution B, condenser 108 of apparatus 100 is preferably utilized in conjunction with flask 102, wherein running water is preferably circulated through condenser 108.

20   Preferably, the optimal composition of passivation solution B approximately includes 1000g/l of $NaNO_3$; however, depending upon the application of the implant and the desired properties of amorphous oxide surface film 5 thereover, the composition of

29

passivation solution B may approximately include a range of 10-2000 g/l of NaNO₃.

With regard to passivation solution C, depending on the chemical composition of the alloys of the metallic implantable device, the pH value of passivation solution C (preferably comprising NaNO₃) may be selectively adjusted to the range of approximately 6.5 to approximately 7.5 to effectively enhance the corrosion resistance of such metal-alloy devices. Accordingly, and preferably with the assistance of a pH meter, neutral passivation solution C is preferably imparted with such a pH value by adjusting and titrating same via the addition of preferably small amounts of NaHCO₃ and diluted HCl solution, wherein equivalent methodologies utilized to manufacture passivation solutions A and B, as described above, may be utilized to manufacture neutral passivation solution C.

For any selected passivation solution A, B or C, passivation time of the implants is preferably conducted for a at least thirty minutes for most implants, and may be conducted for up to two hours for other applicable implants following achievement of boiling temperature of the respective solutions;

however any suitable passivation time may be utilized during passivation step 60 to yield desired results.

Following passivation step 60, all implants are preferably
5   cleansed or rinsed 70 via running water. Thereafter, the implants are preferably dried 80 via circulated cool air, and subsequently packaged 90. Heated air is preferably not utilized to dry the implants following rinsing step 70.

10   Prior to packing 90, sterilization of the implants may be implemented via introduction of the dried implants to gamma rays, ethylene oxide, and/or 70% alcohol, especially if the implants undergoing sterilization are for subsequent cardiovascular application. It should be noted that steam
15   sterilization is not a preferred method of sterilization, as such a process could transfer/change amorphous oxide surface film 5 into a polycrystalline oxide; thus, destroying the significant electrochemical characteristics of amorphous oxide surface film 5.
20

To measure the effectiveness of amorphous oxide surface film 5 and/or implant comprising amorphous oxide surface film 5 thereover, various properties of amorphous oxide surface film 5

may be characterized *in vitro* by the following experimental techniques:

Anodic polarization measurement: Corrosion resistance of different surface oxide films on stainless steel or other implants can be evaluated by cyclic anodic polarization measurement. The cyclic anodic polarization is implemented via a computer-controlled potentiostat (Ex.: EG&G Princeton Applied Research, Model 273). Tests are conducted at 37°C in Ringer's physiological solution with the following composition: NaCl: 9.0 g/l, $CaCl_2$* $2H_2O$:0.17g/l; KCl: 0.4g/l, wherein the solution is buffered with $NaHCO_3$ with a concentration of 2.1g/l and maintained at the normal physiological pH of 7.4. Saturated calomel electrode (SCE) is utilized as the reference and a platinum wire is utilized as the counter electrode. The solution is continuously purged with 5%CO_2/95%air of mixed gas for 1 hour before starting and during the measurement. A scan rate of 0.167mV/s is applied starting at -0.15Vvs. SCE is utilized until a breakdown potential is reached, and potential subsequently reverses. Experimentation is terminated once the reversal scanning potential reaches repassivation potential.

Open-circuit potential (OCP): Open-circuit potential (OCP) of each passivated surface is measured with respect to the standard calomel electrode (SCE) using computer-controlled potentiostat (Ex.: EG&G Princeton Applied Research, Model 273)

5   in aerated Ringer's solution at 37°C. OCP is a critical factor for the formation of thrombosis after implants are deployed into the artery.

Current density at open-circuit potential: Current density

10 at OCP is measured for stainless steel with various surface conditions, and is recorded as a function of time. This electrochemical measurement is designed to investigate the stability of the passivated oxide film and the possibility of releasing positively-charged ions when the implant contacts with

15 body fluid or Ringer's solution.

Transmission electron microscopy (TEM): Characterization of various oxide films are performed by transmission electron microscopy (TEM). The thin oxide film is stripped from the

20 substrate by dissolving the oxidized stainless steel into a 10% bromine-methanol solution at 40°C for thirty minutes, wherein the thin oxide films are retained on the filter paper after the whole solution is filtered. The retained oxide films are

cleaned thoroughly by methanol and then transferred to a copper mesh for TEM examination. Structure is investigated by bright field and selected area diffraction (SAD).

5   Scanning electron microscopy (SEM): Surface morphology of an implant is examined by scanning electron spectroscopy to determine the severity of corrosion or degree of thrombosis. Representative micrographs are taken in a secondary electron imaging mode. To prevent charging problems and enhance the

10   resolution, implants are sputtered with a thin layer of gold.

Auger electron spectroscopy (AES): AES analysis is performed on the passivated surfaces (670 PHI X_i, Physical Electronics, USA) at 5keV with a 9.8nA primary electron beam.

15   Ion etching is performed at a pressure of 10mPa using high purity argon and a raster size 4x4 mm^2, with the corresponding sputtering rate at 2.7nm/min calibrated by SiO_2. The main peaks utilized for determination of the atomic percentage in the depth profiles are O KLL at 510eV, Cr LMM at 49 eV, Fe LMM at 589eV,

20   Mo MNN at 184 eV, and Ni LMM at 844 eV. The atomic percent is calculated from the peak areas with software equipped with AES. Depth profiles are measured by combining AES analysis and argon

34

ion sputter etching to evaluate the oxide layer thickness and the elemental distribution.

Cyclic voltammetry (CV): CV analysis is carried out utilizing the EG&G Potentiostat Model 273 in conjunction with the software Model 253 Version 4.1.1. CV tracings are recorded in aerated Ringer's solution at 37°C from -900mV to +400mV, at a rate of 20mV/sec versus a saturated calomel electrode (SCE) reference electrode. A three-electrode system is utilized throughout the study. The working electrode is drug-coated stainless steel implant, wherein a platinum wire serves as a counter electrode.

Electrochemical Impedance Spectroscopy (EIS): An AC impedance measurement technique is employed to investigate the electrochemical kinetics at the implant-electrolyte interface. The measurement is performed at an open-circuit potential and the frequency is varied in the range of 10^5 Hz to 10^{-5} Hz with an imposed voltage of 5 mV AC (i.e., utilizing Model 6310, EG &G, USA).

The above-discussed *in vitro* characterizations or experiments preferably allow the detection of the properties of

amorphous oxide surface film 5, and other selected oxide films, when submerged in an electrolyte solution, wherein parameters such as capacitance and resistance are generally recorded. Since the thin amorphous oxide surface film 5 acts as a

5   capacitor when the semiconductor device makes contact with physiological fluids or blood, the time it takes for the reaction to take place is an important characteristic of each type of amorphous oxide surface film 5. The time constant, λ, is calculated by the multiplication of the values of capacitance

10 and resistance determined from the impedance measurements.

In addition to *in vitro* characterization of amorphous oxide surface film 5 and/or implants comprising amorphous oxide surface film 5, *in vivo* characterization is also preferably

15 conducted via the following experimental techniques:

Animal Experiment: The potential effect of metal surface treatments on post-stenting neointimal formation is evaluated in abdominal aorta of New-Zealand white rabbits, wherein adult male

20 New-Zealand white rabbits weighing 3.12±0.08kg (2.47-3.52kg), and fed with normal diet, are utilized in this study. The New Zealand rabbits are anesthetized by intra-muscular injection of ketamine (50mg/kg) mixed with xylazine (10mg/kg). Femoral

36

artery was exposed and ligated. A 5 Fr. introducer sheath is passed via arteriotomy retrograde into the abdominal aorta with systemic heparinization (100 USP units/kg) intra-arterially. Balloon catheters are subsequently introduced through this

5   sheath and advanced proximally to the aortic arch via a 0.014 inch guide wire. The stainless steel stents are delivered by an angioplasty balloon catheter. Each stent is then deployed in the lower abdominal aorta by two consecutive balloon inflation pressures of 40 seconds at 8atm to a final diameter of 4mm. The

10 infrarenal abdominal aorta is approximately 3.7mm in diameter yielding a stent/artery ratio of 1.1:1 to 1.2:1. The punctured artery is ligated both proximally and distally. Rabbits received ampicillin immediately after operation.

15   Morphometric Measurement: Cross-section of neointimal and media surface area is determined utilizing computer-assisted digital planimetrys. The intimal area and media area are determined at proximal, middle, and distal site from each stent, and the results are averaged to minimized sampling error.

20

        Tissue Processing: Stented abdominal aortas are harvested after 8 weeks. The harvested stents are fixed by immersion in 4% paraformaldehyde. Stented arterial segments are oriented

from distal to proximal end. The whole segment is dehydrated step wisely with graded alcohols. Specimens are then embedded in epoxy-araldite resin. Multiple stented aortas are serially sectioned from one end to the middle portion of the segment, wherein five even slides per stent from the total 20 sections of each animal are produced. Sectioning is performed by a rotating diamond-coated saw, with the stent struts remaining in situ. The thickness of each slice is about 100-150 μm. Slices are stained with toluidine blue to enhance the areas of media and intima for observation and histology calculation. The extent of deep arterial injury caused by stent struts is quantified histologically in Verhoeff elastin-stained or hematoxylin and eosin.

Thrombosis Study via Experimental Model: Experiments are performed on mongrel dogs with a mean body weight of 17.2±1.6 kg (range, 15.6-18.5kg). After overnight fasting, dogs are sedated with Phenobarbital (5mg/kg), and anesthesia is maintained with 1.5% halothane after endotracheal intubation. Both arterial and venous limbs of fistula are isolated and implanted with stainless steel stents having different surface oxides. Arterial blood gases and pH are monitored periodically and maintained at normal levels by adjusting ventilation rate and

tidal volume. Intensive arterial pressure measurement, oxygen saturation, ECG, and rectal temperature are monitored continuously. A thermostatically controlled blanket is utilized to maintain temperature at 37°C.

5

Referring now more specifically to **FIGS. 3-12,** and with reference to the above-discussed *in vitro* and/or *in vivo* characterization techniques and experiments, properties of implants comprising amorphous oxide surface film 5 (referred to hereinafter as "AO") may be distinguished from those implants comprising an oxide film created via electropolishing processes (referred to hereinafter as "EP"), and implants comprising a polycrystalline oxide film (referred to hereinafter as "PO").

15

With specific reference to **FIGS. 3-4,** oxide structures and particles of AO, EP and PO films may be examined via transmission electron microscopy after proper sample preparation, as described above. Further, crystal structures may be determined by the selected area diffraction (SAD) pattern. Accordingly, **FIGS. 3-4** illustrate that the oxide film created by EP comprises oxide grains in nanometer-scale to micro scale range, as is confirmed by defined rings revealed by the SAD. Oxide particles are in the wide ranges for the PO films.

Unlike the EP and PO films, the diffused rings observed from the SAD for the stainless steel implant coated with AO indicate that oxide particles are in nanometer scale or sub-nanometer scale within amorphous oxide surface film 5, as is

5   shown in the higher magnification of **FIG. 4.**

Referring now more specifically to **FIGS 5A-5C,** illustrated therein are the oxygen and chromium concentration profiles inside AO, EP and PO films, as depicted via the AES depth

10   profiles of oxygen, iron, chromium, and nickel from the passivated stainless steel surfaces/implants. Iron oxide is the dominant chemical composition on the EP and PO passivated stainless steel surface (**FIGS. 5B** and **5C,** respectively), wherein oxygen-rich and chromium-rich profiles are the distinguished

15   features for the AO passivated stainless steel (**FIG. 5A**).

Referring now more specifically to **FIG. 6,** typical results of open-circuit potential (OCP) measurements on the AO, EP and PO oxide films are illustrated. Significant differences in OCP

20   values are found for stainless steels passivated with AO, EP, and PO oxide film. AO treatment has the lowest OCP value (i.e., AO: -102 ± 26 mV; PO: 100 ± 41 mV; EP: 30 ± 22 mV; $P< 0.01$). The lower OCP for AO films is coincident with the suggestion within

the art that an implant with an OCP close to the hydrogen potential could result in a thrombosis-free condition. Accordingly, because a blood vessel and blood possess negative charges in normal conditions, with the blood vessel having a

5   negative potential, then a galvanic current could be induced when a metal with positive potential and charge is implanted within the vessel, and thus result in thrombosis.

Referring now more specifically to **FIG. 7**, typical cyclic

10 anodic polarization scanning curves for each surface condition of AO, EP and PO oxide films are illustrated.   These scanning curves reveal an increase of the breakdown potential of treated samples ranging from 200mV to 800mV, except the stainless steel treated with AO.   That is, no breakdown potential and low

15 passive current density are found for AO treated stainless steel implants.   It should be noted that the presence of a huge hysteresis loop is an indication of the nucleation and growth of corrosion pits.   However, the small loop found on the AO treated stainless steel implant indicates that repassivation potential

20 is higher than the E_{corr} and represents the absence of any pitting degradation.

As may be illustrated with reference to **FIG. 7,** corrosion resistance of the surface treated stainless steel decreases in the order of AO>EP>PO according to the anodic polarization measurement. As such, it is apparent that stainless steel

5   implants passivated with AO significantly improves the corrosion resistant performance of the implants.

Referring now more specifically to **FIGS. 8A-8C,** current density at open-circuit potential (OCP) for the AO, EP and PO

10   films are illustrated. Specifically, unsteady current densities, and spikes of current density, are detected for stainless steel implants passivated with PO and EP (see **FIGS. 8A** and **8B,** respectively). However, consistent negative current density is obtained for the stainless steel implant passivated

15   with AO surface film (see **FIG. 8C**).

Referring now more specifically to **FIG. 9,** illustrated therein is the time constant (T_c) of the AO, EP and PO oxide films on implants, wherein the time constant is obtained by

20   multiplying the values of resistance and capacitance from electrochemical impedance measurements. Specifically, implants with a higher value of time constant could result in a lower degree of thrombosis, wherein the difference becomes more

significant when heparin is administrated in conjunction with implantation of the implant.

Referring now more specifically to **FIGS. 10A** and **10B,**
5   illustrated therein are implants with AO film and EP film, respectively, wherein a one-hour thrombosis study indicates that there is about a 90% reduction of thrombosis when heparin is utilized in conjunction with an implant metal with AO film, as opposed to the thrombotic condition developing with the EP film
10   implant and heparin combination.

Referring now to **FIGS. 11A-11C,** illustrated therein is the effect of implants with AO, EP, and PO, respectively, on neointimal hyperplasia and ensuing lumen restenosis, as followed
15   over an eight-week period. Neointimal hyperplasia is regarded as one of the major factors responsible for lumen restenosis following intravascular stent implantation. As depicted in respective **FIGS. 11A** and **11B,** post-stenting neointima thickening was reduced by 50% for the stent group with AO film versus the
20   stent group with an EP film.

Referring now more specifically to **FIG. 12,** illustrated therein is the cyclic voltammetry of an AO film implant utilized

as a platform for drug-coating. Specifically, the quantity of drugs on the implants can be determined by the cyclic voltammetry, and may be expressed as current density in a unit of $\mu A/cm^2$. Apparently, the eluting profile can be changed from a

5   faster releasing rate to a slower eluting profile based upon the chemistries inside the AO layer. For an efficacious drug-eluting stent, the life-span must last at least 60 days after implantation of the stent to minimize the degree of neointima. Practically, the eluting profile for drugs (such as heparin,

10 magnolol, tranilast, SIROLIMUS, TAXOL, and the like) from AO films, *in-vitro*, on stainless steel, can reach and even exceed the critical 60-day minimum requirement.

Having thus described exemplary embodiments of the present

15 invention, it should be noted by those skilled in the art that the within disclosures are exemplary only, and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments

20 illustrated herein, but is limited only by the following claims.